Abstract: Neurodegenerative diseases are widespread and the increasing number of patients with these diseases can no longer be ignored. Dementia is a symptom of many neurodegenerative diseases, and Alzheimer’s disease (AD), which is associated with memory and learning disabilities, accounts for approximately 60 to 80% of all dementia cases (Wyss-Coray, 2016). In the United States, it is estimated that 13.8 million people over the age of 65 years will be affected by AD in 2050 (Alzheimer’s Association, 2020). Moreover, the onset of AD is closely related to aging, and as such, AD occurs at a frequency of 50% in people over the age of 95 years. Although progress in medical science has contributed to an increase in the average human lifespan, advances in AD treatment strategies have been unable to keep up with the increasing number of elderly individuals. Most drugs targeting AD merely delay the progression of the disease, without providing a bona fide treatment. Moreover, because the life expectancy of AD patients is 3 to 11 years after diagnosis, an effective therapy for AD is urgently required (Alzheimer’s Association, 2020).